Research programme: antithrombotic peptides - BioxodesAlternative Names: Ir-CPI
Latest Information Update: 16 Jan 2014
At a glance
- Originator Free University of Brussels
- Developer Bioxodes
- Class Peptides
- Mechanism of Action Serine protease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Thrombosis
Most Recent Events
- 08 Jan 2014 Preclinical trials in Thrombosis (prevention) in Belgium (IV)